Uteron Pharma is a pharmaceutical development company and part of Actavis, Inc. Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis is focused on enhancing its commercial position in global generics, brands and biologic pharmaceutical products, targeting products that will deliver long-term growth while maintaining a competitive cost structure.
Uteron Pharma is designated as one of Actavis’ Centre of Excellence for women’s healthcare delivering product development; cGMP manufacturing of hormonal intra-uterine devices (IUD) and quality/regulatory expertise from a custom-designed facility located in Liège, Belgium.
Uteron Pharma is active in four domains: Contraception & Fertility, Menopause & Osteoporosis, Vaginal infections and Oncology; and also operates a GMP approved 3,000 square meters production facility in Grâce-Hollogne (Belgium).
The company is currently developing a new generation of oral contraceptives based on natural estrogen, hormonal intra-uterine devices, an innovative diagnostic test to increase in vitro fertilization success rate and treatments for cervical dysplasia and recurrent vaginal infections.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.
Actavis has manufacturing, R&D and commercial operations in more than 60 countries, with access to more than 5 billion of the world’s consumers.
Our commercial operations and facilities are strategically located around the world to maximize development opportunities, ensure an uninterrupted supply of product to market and provide industry-leading customer service.